☆ 4.6 Editorial Material

The IBD Disability Index should become a Major Secondary Endpoint in Clinical Practice and in Clinical Trials

JOURNAL OF CROHNS & COLITIS (2016)

Get Full Text
Add to Collection

Journal

JOURNAL OF CROHNS & COLITIS
Volume 10, Issue 12, Pages 1375-1377

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/ecco-jcc/jjw156

Keywords

-

Categories

Gastroenterology & Hepatology

Funding

  1. Merck
  2. Abbvie
  3. Janssen
  4. Genentech
  5. Mitsubishi
  6. Ferring
  7. Norgine
  8. Tillots
  9. Vifor
  10. Therakos
  11. Pharmacosmos
  12. Pilege
  13. BMS
  14. UCB-pharma
  15. Hospira
  16. Celltrion
  17. Takeda
  18. Biogaran
  19. Boerhinger-Ingelheim
  20. Lilly
  21. Pfizer
  22. HAC-Pharma
  23. Index Pharmaceuticals
  24. Amgen
  25. Sandoz
  26. Forward Pharma GmbH
  27. Celgene
  28. Biogen
  29. Lycera
  30. Samsung Bioepis

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.